Compare Oscar Health Inc (OSCR) vs Tesla, Inc. (TSLA) Price & Performance

Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.

Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.

Tesla (TSLA) trades at $368.16, up 3.98% today, amid a bullish technical signal and recent earnings beats despite a Q2 2026 miss. The stock shows elevated valuation multiples with a P/E of 340.89 and P/S of 12.57, while profitability metrics like a 3.67% net income margin reflect competitive pressures. Positive developments include regulatory approval for driver-assistance software in Europe and a potential cheaper EV launch, though cash flow trends indicate heavy investment spending.

The outlook balances innovation potential in autonomy and energy against valuation concerns and execution risks. Near-term catalysts include Q3 2026 earnings, with the consensus price target of $398.38 suggesting modest upside. Key risks are slowing auto demand, high capex, and reliance on future technology adoption to justify current premiums.